Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation

• Published in: Case reports in hematology Vol. 2020; no. 2020; pp. 1 - 5
• Main Authors: Čepulytė, Rūta, Pečeliūnas, Valdas, Žučenka, Andrius
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 15-10-2020; Hindawi; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Antimitotic agents; Antineoplastic agents; Bone marrow; Care and treatment; Case Report; Case reports; Development and progression; Diarrhea; Disease; Diseases; Drug resistance; Gene mutations; Genetic aspects; Health aspects; Inflammatory bowel disease; Kinases; Lung cancer; Melanoma; Metronidazole; Multiple myeloma; Mutation; Patients; Relapse; Targeted cancer therapy; Thyroid cancer; Transplants & implants
• ISSN: 2090-6560; 2090-6579
• DOI: 10.1155/2020/8894031

Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refractory (R/R) disease course, which poses a major therapeutic challenge. New therapies, including BRAF V600E mutation targeting, may become a new treatment option for R/R MM. In combination with mitogen-activated protein kinase inhibitors (MEKi), BRAF inhibitors (BRAFi) could provide better tailored clinical management, although experience in this field is lacking. To this date, there is only one case describing R/R MM treatment with BRAFi vemurafenib and MEKi cobimetinib. This is the first case presenting a R/R MM patient treated with BRAFi dabrafenib and MEKi trametinib.